• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AFYX Therapeutics touts study results for biodegradable oral adhesive patch

March 11, 2021 By Sean Whooley

AFYX TherapeuticsAFYX Therapeutics announced today that a study observed successful transmucosal delivery of a corticosteroid with its Rivelin patch.

The Rivelin clobetasol patch (Rivelin-CLO) is a novel adhesive patch designed to deliver a therapeutic agent to wet tissue surfaces. The study, published in The European Journal of Oral Sciences, was the first to show the successful transmucosal delivery of the corticosteroid using electrospun patch technology, according to a news release.

Rivelin-CLO proved to deliver the drug and the study showed that the drug retained its anti-inflammatory activity. The biodegradable, oral adhesive patch is designed for local delivery of clobetasol to treat symptomatic oral lichen planus (OLP) lesions.

The patch utilizes electrospinning technology to adhere to the oral cavity for an average of 90 minutes. It can adhere to other wet tissue areas for approximately 9.5 hours while delivering a steady dose of therapeutics to the lesion.

AFYX recently completed a Phase 2 trial for Rivelin-CLO, administering a 20μg dose of the drug. The trial revealed a statistically significant improvement in the ulcer area and continued to show improvement through the end of four weeks, AFYX said.

“Rivelin-CLO has the power to deliver targeted, localized quantities of clobetasol to diseased tissue in the mouth for patients with OLP, a condition for which there are no approved therapies,” AFYX Therapeutics CEO Dr. Nishan de Silva said in the release. “This new mucoadhesive patch technology holds great promise for the treatment of patients with mucosal diseases. These are conditions which may benefit from treatments such as corticosteroids, anesthetics and analgesics, all of which require specific, controlled delivery directly to wet tissue.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: AFYX Therapeutics, wearables

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS